ClinicalTrials.gg
CompletedNCT05912296Updated May 1, 2025

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

A Phase 1 interventional study of RBD7022 and RBD7022 in Hyperlipemia, sponsored by Suzhou Ribo Life Science Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Suzhou Ribo Life Science Co. Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies in Hyperlipidemias with a site in China — 30 open to participants now, 37 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
55th of 78
80 · median 155
Started
2023
with 9 others
Phase 1
19 of 94
4 open now
Registered
50th of 94
by date

Among the 94 studies in Hyperlipidemias with a site in China, this one is the 55th largest by enrollment of the 78 interventional ones that give a count, is one of 10 that started in 2023, is one of 19 in phase 1, and was the 50th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 94 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

This is a randomized, single blind, placebo controlled, single center phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of subcutaneously administered RBD7022 in participants with normal or elevated LDL-c cholesterol. The study will be performed in 2 phases: single ascending dose (SAD) phase and multiple ascending doses (MAD) phase in participants. The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information in each cohort.

03

Conditions studied

  • Hyperlipemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, aged 18 to 65 years, inclusive
  • between 17 and 28 kg/m2 , inclusive
  • LDL-C normal or elevated at screening and baseline.
  • Willing to comply with protocol required visit schedule and visit requirements and provide written .
  • The clinical laboratory examination of the subjects was within the normal range, or abnormal but had no clinical significance as judged by the investigators, and did not affect the study results;
  • Vital signs, physical examination, , ultrasound showed normal or abnormal but no as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • With a clear history of primary diseases of major organs, the subject is not suitable to participate in this study considered by the investigator;
  • Diagnosis of diabetes mellitus;
  • Pregnant or breastfeeding women;
  • Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    RBD7022 SAD experimental group

    Subjects in SAD experimental groups will receive a single subcutaneous injection of RBD7022 on Day 0.

    Drug: RBD7022

  • Experimental
    RBD7022 MAD experimental group

    Subjects in MAD experimental groups will receive one subcutaneous injection of RBD7022 on Day 0 and another subcutaneous injection of RBD7022 on Day 28.

    Drug: RBD7022

  • Placebo comparator
    Placebo SAD group

    Subjects in SAD placebo groups will receive a single subcutaneous injection of placebo on Day 0.

    Drug: Placebo

  • Placebo comparator
    Placebo MAD group

    Subjects in MAD placebo groups will receive one subcutaneous injection of placebo on Day 0 and another subcutaneous injection of placebo on Day 28 .

    Drug: Placebo

Interventions

  • DrugRBD7022

    Subcutaneously Administered RBD7022 in Healthy Subjects.

  • DrugRBD7022

    Subcutaneously Administered RBD7022 in Healthy Subjects.

  • DrugPlacebo

    Subcutaneously Administered Placebo in Healthys Subject.

  • DrugPlacebo

    Subcutaneously Administered Placebo in Healthys Subject.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0

    By the examination of vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory examination, the investigator will make an assessment of intensity for each AE and SAE reported during the study according to CTCAE V5.0

    Time frame: SAD up to Day 180; MAD up to Day 208

Secondary outcomes

  1. The serum LDL-C level after subject dosing RBD7022

    measure the LDL-C level in blood by lab examination and eveluate the effect of RBD7022 on Circulating LDL-c Levels (Determination of % Lowering of LDL-c to treatment/Baseline LDL-c Level)

    Time frame: SAD up to Day 180; MAD up to Day 208

  2. The serum PCSK9 level after subject dosing RBD7022

    measure the pcsk9 level in blood by lab examination and eveluate the effect of RBD7022 on Circulating PCSK9 Levels (Determination of % Lowering of PCSK9 to treatment/Baseline PCSK9 Level).

    Time frame: SAD up to Day 180; MAD up to Day 208

  3. Other blood lipoprotein and lipid parameters besides LDL-c

    measure other blood lipoprotein and lipid parameters besides LDL-c in blood by lab examination and eveluate % change and absolute change in other lipoprotein and lipid parameters(TC、TG、Lp (a)、HDL-C、non HDL-C、Apo B、Apo A1、Apo A 1/ Apo B ratio) from baseline up to Day 208

    Time frame: SAD up to Day 180; MAD up to Day 208

  4. The effect of RBD7022 monotherapy or RBD7022 combination with statin in patients with elevated LDL-C

    measure the LDL-C and pcsk9 level in blood by lab examination and assess % change and absolute change in LDL-c and PCSK9 from baseline up to Day 208

    Time frame: SAD up to Day 180; MAD up to Day 208

  5. To characterize the pharmacokinetic parameter Cmax

    Plasma Maximum concentration (Cmax)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  6. To characterize the pharmacokinetic parameter Tmax

    Time to maximum concentration (Tmax)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  7. To characterize the pharmacokinetic parameter AUC0-t

    Area under the concentration-time curve from 0 to the collection time t (AUC0-t)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  8. To characterize the pharmacokinetic parameter t1/2

    Half-Life (t1/2)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  9. To characterize the pharmacokinetic parameter λz

    Elimination rate constant (λz)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  10. To characterize the pharmacokinetic parameter CL/F

    Oral clearance (CL/F)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  11. To characterize the pharmacokinetic parameter Vz/F

    Volume of distribution in the terminal elimination period (Vz/F)

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

  12. To characterize the pharmacokinetic parameter AUC0-inf

    Area under the concentration-time curve from 0 to infinity

    Time frame: SAD: within 60 min before dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24, 48 and 72 hours after dosing; MAD: within 60 minutes before day 0 and day 28 dosing, and at 15min, 30min, 1, 2, 4, 6, 8,12, 24 ,48 and 72 hours after Day 0 and day 28 dosing

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 010, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Mar 2025, 21 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 21 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2023
First posted
Jun 22, 2023
StartActual
May 30, 2023
Primary completionActual
Mar 4, 2025
CompletionActual
Mar 31, 2025
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05912296
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
May 30, 2023
Primary completion
Mar 4, 2025
Completion
Mar 31, 2025
Last update
May 1, 2025

Study contacts

Rui Chen, Doctor
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion